EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Akero Therapeutics's enterprise value is $558.42 Mil.
Akero Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Akero Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Akero Therapeutics's EV-to-Revenue or its related term are showing as below:
AKRO's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.95 * Ranked among companies with meaningful EV-to-Revenue only.
The historical data trend for Akero Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akero Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Akero Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akero Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akero Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Akero Therapeutics's EV-to-Revenue falls into.
Akero Therapeutics's current Enterprise Value is $558.42 Mil.
Akero Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics's share price for today is $20.30.
Akero Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Akero Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Akero Therapeutics (Akero Therapeutics) Business Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKRO has been successfully added to your 